Rotavirus vaccination: a concise review.

Area of Science:

• Vaccinology
• Pediatric Infectious Diseases
• Public Health

Background:

• Live attenuated oral rotavirus vaccines have evolved since the 1980s, with current options including Rotarix (RV1) and RotaTeq (RV5).
• Early vaccine RotaShield was withdrawn due to intussusception risks, prompting rigorous safety and efficacy testing for subsequent vaccines.
• Rotavirus gastroenteritis (RVGE) remains a significant global health concern, particularly in infants.

Purpose of the Study:

• To evaluate the safety and efficacy of currently licensed oral rotavirus vaccines.
• To assess the real-world effectiveness of rotavirus vaccines in diverse geographical settings.
• To understand factors influencing the global adoption of rotavirus vaccination programs.

Main Methods:

• Review of clinical trial data for Rotarix and RotaTeq, including over 60,000 infants per vaccine.
• Analysis of field effectiveness data from Europe, USA, Latin America, and Africa.
• Examination of national immunization program data and factors affecting vaccine introduction.

Main Results:

• Both Rotarix and RotaTeq demonstrate high effectiveness (>90%) against severe RVGE in Europe and the USA, and around 80% in Latin America.
• Efficacy rates in African trials range from 50% to 80%, indicating regional variations.
• Rotavirus vaccination is established in numerous countries, but slow progress in Europe is linked to low mortality, cost-benefit analyses, and persistent intussusception concerns.

Conclusions:

• Current oral rotavirus vaccines are effective in preventing severe rotavirus gastroenteritis, with varying effectiveness by region.
• Global implementation is increasing, yet challenges remain, particularly in Europe.
• Ongoing monitoring for safety, especially intussusception, is crucial for vaccine acceptance and public health policy.